2653 monitored
← Actor desksRead-only · existing recordsClassic graph view ↗

Sentinels / Actor desk

Lab Medicine

organization · Registry status: unverified

d8482795-e1b4-5c8b-b8a7-6cfbc4548727

Evidence, not intent.

Public-source event mentions and stored signals. Adjacency does not establish causation, coordination, or an actor's position.

No claim of complete coverage or live monitoring.

Observation window

UTC dates, inclusive · maximum 90 days. Applies to events and anomalies only.

Recent observations / timeline

The source record

43 distinct events shown, newest first. Headlines may be generated summaries; inspect the source before repeating a claim.

  1. Recent Analysts’ Ratings Updates for Disc Medicine (IRON)

    Recorded role: co mention · TAX_FNCACT_CHIEF_EXECUTIVE_OFFICER

    Open source ↗
  2. BeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Bump from Royal Bank Of Canada

    Recorded role: co mention · TAX_ECON_PRICE

    Open source ↗
  3. Cardiologist Reveals How Your Triglyceride Levels Reflect Your Last 24 Hours of Eating - AOL

    Recorded role: co mention · TAX_FNCACT_CHIEF

    Open source ↗
  4. BeOne Medicines (NASDAQ:ONC) Issues Quarterly Earnings Results

    Recorded role: co mention · TAX_DISEASE_OVERWEIGHT

    Open source ↗
  5. BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

    Recorded role: co mention · MEDICAL

    Open source ↗
  6. BCHS Insider: BCHS recognized as Choosing Wisely Canada Hospital

    Recorded role: co mention · TAX_FNCACT_SURGEON

    Open source ↗
  7. BCHS Insider: BCHS recognized as Choosing Wisely Canada Hospital

    Recorded role: co mention · GENERAL_HEALTH

    Open source ↗
  8. U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell Lymphoma

    Recorded role: co mention · MEDIA_SOCIAL

    Open source ↗
  9. AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

    Recorded role: co mention · TAX_DISEASE_HEART_FAILURE

    Open source ↗
  10. labnews.co.uk: Monica Dugaesescu, Federico Angelo Cazzaniga, Galina Coltuclu (tax disease neurodegenerative diseases, tax disease blood cancer)

    Recorded role: co mention · TAX_DISEASE_NEURODEGENERATIVE_DISEASES

    Open source ↗
  11. AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS

    Recorded role: co mention · MOVEMENT_GENERAL

    Open source ↗
  12. BeOne's BGB-B2033 Records a 36% Response Rate in Phase 1 Liver Cancer Study | EconoTimes

    Recorded role: co mention · WB_2453_ORGANIZED_CRIME

    Open source ↗
  13. IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

    Recorded role: co mention · WB_1921_PRIVATE_SECTOR_DEVELOPMENT

    Open source ↗
  14. IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

    Recorded role: co mention · ECON_ENTREPRENEURSHIP

    Open source ↗
  15. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_DISEASE_GASTROINTESTINAL

    Open source ↗
  16. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · AFFECT

    Open source ↗
  17. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_FNCACT_CHIEF

    Open source ↗
  18. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_DISEASE_HEPATOCELLULAR_CARCINOMA

    Open source ↗
  19. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_2024_ANTI_CORRUPTION_AUTHORITIES

    Open source ↗
  20. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_1160_SHOCKS_AND_VULNERABILITY

    Open source ↗
  21. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · SCIENCE

    Open source ↗
  22. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_845_LEGAL_AND_REGULATORY_FRAMEWORK

    Open source ↗
  23. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · EPU_POLICY_REFORM

    Open source ↗
  24. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_1614_NUTRITIONAL_PROGRAMS

    Open source ↗
  25. BeOne Medicines Ltd.: BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_756_VULNERABLE_GROUPS

    Open source ↗
  26. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_346_COMPETITIVE_INDUSTRIES

    Open source ↗
  27. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_DISEASE_THROMBOCYTOPENIA

    Open source ↗
  28. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · WB_346_COMPETITIVE_INDUSTRIES

    Open source ↗
  29. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · WB_969_CAPITAL_MARKETS_LAW_AND_REGULATION

    Open source ↗
  30. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · LEGISLATION

    Open source ↗
  31. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · TAX_WORLDMAMMALS_HUMAN

    Open source ↗
  32. Amgen Foundation Tops $75 Million in Hands-On Biotechnology Education, Reaching 100,000 Students a Year

    Recorded role: co mention · AFFECT

    Open source ↗
  33. Disc Medicine (IRON) – Research Analysts’ Recent Ratings Updates

    Recorded role: co mention · TAX_FNCACT_CHIEF

    Open source ↗
  34. Allstate Upgraded, Dell Technologies Downgraded: Updated Rankings on Top Blue-Chip Stocks

    Recorded role: co mention · Unclassified event

    Open source ↗
  35. BeOne Medicines (NASDAQ:ONC) Hits New 52-Week High – Should You Buy?

    Recorded role: co mention · EPU_ECONOMY_HISTORIC

    Open source ↗
  36. Contrasting PainReform (NASDAQ:PRFX) & BeOne Medicines (NASDAQ:ONC)

    Recorded role: co mention · TAX_ECON_PRICE

    Open source ↗
  37. Student Health’s scribe program offers graduates clinical experience beyond scribing

    Recorded role: co mention · TAX_FNCACT_CHIEF

    Open source ↗
  38. Insider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells 31,027 Shares of Stock

    Recorded role: co mention · WB_1921_PRIVATE_SECTOR_DEVELOPMENT

    Open source ↗
  39. Top 10 Holdings | Company Announcement | Investegate

    Recorded role: co mention · ECON_STOCKMARKET

    Open source ↗
  40. NEW YORK BLOOD CENTER ENTERPRISES APPOINTS MEGHAN DELANEY, DO, MPH, AS NEXT PRESIDENT & CHIEF EXECUTIVE OFFICER

    Recorded role: co mention · APPOINTMENT

    Open source ↗
  41. BeOne Medicines (NASDAQ:ONC) Price Target Raised to $420.00

    Recorded role: co mention · TAX_FNCACT_CHIEF_EXECUTIVE

    Open source ↗
  42. Mind Medicine (MindMed) (OTCMKTS:MMEDF) Stock Price Down 2.6% – Here’s What Happened

    Recorded role: co mention · EPU_CATS_MIGRATION_FEAR_FEAR

    Open source ↗
  43. Global survey finds gaps in pediatric cardiac troponin testing

    Recorded role: co mention · CRISISLEX_CRISISLEXREC

    Open source ↗

Signals to inspect

Anomalies

Latest 10 in the selected window (up to 10). Detector output, not verified conclusions.

low · volume spike

Volume spike: 2 events in window (2.0x baseline of 1.0 expected)

high · new connection

New connection: 3 previously unseen co-actor(s) detected (known network: 74)

high · new connection

New connection: 11 previously unseen co-actor(s) detected (known network: 66)

high · new connection

New connection: 15 previously unseen co-actor(s) detected (known network: 58)

low · volume spike

Volume spike: 2 events in window (2.0x baseline of 1.0 expected)

high · new connection

New connection: 6 previously unseen co-actor(s) detected (known network: 52)

high · new connection

New connection: 5 previously unseen co-actor(s) detected (known network: 47)

medium · volume spike

Volume spike: 3 events in window (3.0x baseline of 1.0 expected)

low · volume spike

Volume spike: 2 events in window (2.0x baseline of 1.0 expected)

high · new connection

New connection: 3 previously unseen co-actor(s) detected (known network: 44)

Narrative context

Unresolved threads

Latest 20 at most, across all dates. Stored narratives require human review.

No unresolved threads recorded.

Stored connections

Relationships

Up to 50 records ordered by evidence count, across all dates. Co-mentions indicate association in source material, not affiliation or coordination.

Ask this desk

Desk analyst

Read-only questions about Lab Medicine's stored record. Answers cite only records retrieved for that turn; a citation chip opens the existing inspection view. Absence of matches is not evidence of inactivity.

Operator sign-in is required. Sign in

Identity is the existing actor registry record. Entity resolution and source coverage may be incomplete.